One-Time gene injection aims to halt rare eye disease
NCT ID NCT05832684
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a single injection of ZVS101e, a gene therapy that delivers a working copy of the CYP4V2 gene directly into the retina. It is for adults with Bietti's crystalline dystrophy, a rare inherited condition that leads to progressive vision loss. The trial will check whether the treatment is safe and can help preserve or improve eyesight.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZVS101e (a gene therapy carrying a working copy of the CYP4V2 gene)
What this could lead to
If successful, this could become the first treatment to slow or stop vision loss in people with Bietti's crystalline dystrophy.
What could go wrong
This is an early-phase trial with only 24 participants, so results may not apply to everyone. Gene therapy injections carry risks like inflammation or retinal damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIETTI'S CRYSTALLINE DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
Tianjin Medical University Eye Hospital
Tianjin, Tianjin Municipality, 300392, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China